Sumeet Bhanvadia1, Kayvan Kazerouni2, Soroush T Bazargani1, Gus Miranda1, Jie Cai1, Siamak Daneshmand1, Hooman Djaladat3,4. 1. Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA. 2. USC School of Medicine, Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA. 3. Norris Comprehensive Cancer Center, USC Institute of Urology, Los Angeles, CA, USA. djaladat@med.usc.edu. 4. University of Southern California, 1441 Eastlake Ave, Suite 7416, Los Angeles, CA, 90089, USA. djaladat@med.usc.edu.
Abstract
PURPOSE: To validate the relationship between ABO blood type and risk of VTE post-RC in a large retrospective database. METHODS: Patients with urothelial bladder cancer (UBC) who underwent RC (intent-to-cure) for whom ABO blood type was available between 2003 and 2015 were identified from our IRB-approved database. VTE was defined as deep vein thrombosis (DVT) or pulmonary embolism (PE) within 90 days of surgery. VTE prophylaxis consisted of immediate postoperative Coumadin (2003-2009), unfractionated heparin (UFH) during hospitalization (2009-2015), and UFH during hospitalization plus 4 weeks of enoxaparin after discharge (2013-2015). Univariable and multivariable analyses of the association of ABO blood type with postoperative, symptomatic VTE and oncologic outcomes were performed. RESULTS: Of 1341 patients, 595 (44.4%) were ABO type O and 746 (55.6%) were non-O (A, B and AB). 90 patients were diagnosed with VTE within 90 days of surgery (6.7%) (43% DVT-only, 57% PE ± DVT). On multivariable analysis non-O blood type was associated with a nearly twofold increased risk of VTE (OR = 1.94, 95% CI 1.215-3.098, p = 0.004). No difference in recurrence-free survival or overall survival was seen between ABO groups. CONCLUSION: Non-O blood type is an independent, non-modifiable risk factor for postoperative VTE after RC. More comprehensive counseling and thromboprophylaxis should be considered in this high-risk group.
PURPOSE: To validate the relationship between ABO blood type and risk of VTE post-RC in a large retrospective database. METHODS:Patients with urothelial bladder cancer (UBC) who underwent RC (intent-to-cure) for whom ABO blood type was available between 2003 and 2015 were identified from our IRB-approved database. VTE was defined as deep vein thrombosis (DVT) or pulmonary embolism (PE) within 90 days of surgery. VTE prophylaxis consisted of immediate postoperative Coumadin (2003-2009), unfractionated heparin (UFH) during hospitalization (2009-2015), and UFH during hospitalization plus 4 weeks of enoxaparin after discharge (2013-2015). Univariable and multivariable analyses of the association of ABO blood type with postoperative, symptomatic VTE and oncologic outcomes were performed. RESULTS: Of 1341 patients, 595 (44.4%) were ABO type O and 746 (55.6%) were non-O (A, B and AB). 90 patients were diagnosed with VTE within 90 days of surgery (6.7%) (43% DVT-only, 57% PE ± DVT). On multivariable analysis non-O blood type was associated with a nearly twofold increased risk of VTE (OR = 1.94, 95% CI 1.215-3.098, p = 0.004). No difference in recurrence-free survival or overall survival was seen between ABO groups. CONCLUSION: Non-O blood type is an independent, non-modifiable risk factor for postoperative VTE after RC. More comprehensive counseling and thromboprophylaxis should be considered in this high-risk group.
Authors: Giancarlo Agnelli; Giorgio Bolis; Lorenzo Capussotti; Roberto Mario Scarpa; Francesco Tonelli; Erminio Bonizzoni; Marco Moia; Fabio Parazzini; Romina Rossi; Francesco Sonaglia; Bettina Valarani; Carlo Bianchini; Gualberto Gussoni Journal: Ann Surg Date: 2006-01 Impact factor: 12.969
Authors: Daniel J Culkin; Emilio J Exaire; David Green; Mark S Soloway; Andreas J Gross; Maheshbhai R Desai; James R White; Deborah J Lightner Journal: J Urol Date: 2014-05-21 Impact factor: 7.450
Authors: Tobias Klatte; Evanguelos Xylinas; Malte Rieken; Morgan Rouprêt; Harun Fajkovic; Christian Seitz; Pierre I Karakiewicz; Yair Lotan; Marko Babjuk; Michela de Martino; Shahrokh F Shariat Journal: Urol Oncol Date: 2014-02-02 Impact factor: 3.498
Authors: A Y Nossent; V VAN Marion; N H VAN Tilburg; F R Rosendaal; R M Bertina; J A VAN Mourik; H C J Eikenboom Journal: J Thromb Haemost Date: 2006-10-16 Impact factor: 5.824
Authors: Joseph J Pariser; Shane M Pearce; Blake B Anderson; Vignesh T Packiam; Vivek N Prachand; Norm D Smith; Gary D Steinberg Journal: J Urol Date: 2016-08-26 Impact factor: 7.450
Authors: Boris Gershman; Daniel M Moreira; Matthew K Tollefson; Igor Frank; John C Cheville; Prabin Thapa; Robert F Tarrell; Robert Houston Thompson; Stephen A Boorjian Journal: Urol Oncol Date: 2015-08-29 Impact factor: 3.498
Authors: Francesco Dentali; Anna Paola Sironi; Walter Ageno; Sara Turato; Carlo Bonfanti; Francesco Frattini; Silvia Crestani; Massimo Franchini Journal: Semin Thromb Hemost Date: 2012-06-27 Impact factor: 4.180
Authors: Matthew K Tollefson; R Jeffrey Karnes; Laureano Rangel; Rachel Carlson; Stephen A Boorjian Journal: J Urol Date: 2013-10-17 Impact factor: 7.450
Authors: Wilhelmina C M Duivenvoorden; Siamak Daneshmand; Daniel Canter; Yair Lotan; Peter C Black; Hamidreza Abdi; Bas W G van Rhijn; Elisabeth E Fransen van de Putte; Piotr Zareba; Ilmari Koskinen; Wassim Kassouf; Samer L Traboulsi; Janet E Kukreja; Peter J Boström; Bobby Shayegan; Jehonathan H Pinthus Journal: J Urol Date: 2016-06-14 Impact factor: 7.450